These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26179864)

  • 21. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.
    Gafter-Gvili A; Ribakovsky E; Mizrahi N; Avigdor A; Aviv A; Vidal L; Ram R; Perry C; Avivi I; Kedmi M; Nagler A; Raanani P; Gurion R
    Leuk Lymphoma; 2016; 57(1):63-9. PubMed ID: 25944378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies.
    Gandhi V
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):4-11. PubMed ID: 12170425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
    Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
    Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bendamustine combined regimen for Hodgkin's lymphoma.
    Venkatesan P
    Lancet Oncol; 2016 Aug; 17(8):e326. PubMed ID: 27425812
    [No Abstract]   [Full Text] [Related]  

  • 25. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bendamustine: a new look at an old drug.
    Kalaycio M
    Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced bendamustine for elderly patients with follicular lymphoma.
    Masamoto Y; Shimura A; Kurokawa M
    Ann Hematol; 2022 Mar; 101(3):713-715. PubMed ID: 34152427
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term safety experience with bendamustine for injection in a real-world setting.
    Martin P; Barr PM; James L; Pathak A; Kahl B
    Expert Opin Drug Saf; 2017 Jun; 16(6):647-650. PubMed ID: 28395515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine in multiple myeloma.
    Gentile M; Vigna E; Recchia AG; Morabito L; Mendicino F; Giagnuolo G; Morabito F
    Eur J Haematol; 2015 Nov; 95(5):377-88. PubMed ID: 26085055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program.
    Gentilini F; Brunetti G; Finsinger P; Chisini M; Cartoni C; Foà R; Petrucci MT
    Leuk Lymphoma; 2016 Jul; 57(7):1716-8. PubMed ID: 26694230
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
    Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New drugs in the treatment of multiple myeloma].
    Oriol A; Motlló C
    Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
    Elsoueidi R; Mulat A; Mourad H
    J Oncol Pharm Pract; 2014 Aug; 20(4):309-11. PubMed ID: 24847047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
    Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
    Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
    [No Abstract]   [Full Text] [Related]  

  • 35. Bendamustine: inadequate or outdated data.
    Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
    Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
    Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
    [No Abstract]   [Full Text] [Related]  

  • 37. Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials.
    Gafter-Gvili A; Gurion R; Raanani P; Shpilberg O; Vidal L
    Hematol Oncol; 2017 Dec; 35(4):424-431. PubMed ID: 27734524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.
    Leng S; Bhutani D; Raza S; Assal A; Pan S; Hu J; Wei A; Mapara M; Lentzsch S
    Blood Cancer J; 2020 Feb; 10(2):13. PubMed ID: 32015343
    [No Abstract]   [Full Text] [Related]  

  • 39. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
    [No Abstract]   [Full Text] [Related]  

  • 40. Bendamustine conditioning for refractory type I cryoglobulinemia.
    Martin M; Lipsker D; Fornecker LM; Toussaint E; Martin T
    Joint Bone Spine; 2016 Oct; 83(5):591-2. PubMed ID: 26677988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.